Fluorine in the Pharmaceutical Industry: FDA‐Approved Fluorine‐Containing Drugs in 2024
Chemistry – A European Journal · 2025-05 · 31 (25)
DOI: 10.1002/chem.202500662 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Chemistry – A European Journal, online erschienen am 21.04.2025. Verfasst von Youlong Du und 9 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Co-Innovation Center of Efficient Processing and Utilization of Forest Resources, International Innovation Center for Forest Chemicals and Ma…. Hauptthemen laut MEDLINE: Fluorine. Die Arbeit wurde bisher 121-mal zitiert (Crossref) und nennt 176 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Research, Development and Innovation Office of Hungary.
Abstract (Originalsprache)
Fluorine has become an essential element in the development of modern pharmaceuticals, due to its unique chemical properties that can significantly enhance the biological activity, metabolic stability, and lipophilicity of drug molecules. This review explores recent advancements in the synthesis and application of fluorine‐containing drugs approved by the US Food and Drug Administration (FDA) in 2024. These novel drugs demonstrate improved efficacy and safety profiles, addressing a range of therapeutic areas including oncology, infectious diseases, metabolic disorders and genetic disorders that affect the adrenal glands. The incorporation of fluorine atoms into drug candidates has facilitated the development of molecules with optimized pharmacokinetic and pharmacodynamic properties, leading to better patient outcomes. The review further discusses the synthetic methodologies employed, the structural characteristics of these drugs, and their clinical implications, providing insights into the ongoing innovation within the pharmaceutical industry driven by fluorine chemistry.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jiangsu Co-Innovation Center of Efficient Processing and Utilization of Forest Resources, International Innovation Center for Forest Chemicals and Materials, College of Chemical Engineering, Nanjing Forestry University,…
- Department of Intensive Care Unit, Geriatric Hospital of Nanjing Medical University, No.30 Luojia Road, Nanjing, 210024, China.
- Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, Freie Universität Berlin, Königin-Luise-Straße 2+4, 14195, Berlin, Germany.
- School of Allied Medical Sciences, Delhi Skill and Entrepreneurship University, Dwarka, New Delhi, 110077, India.
- Department of Biomedical Science, Acharya Narendra Dev College, University of Delhi, Kalkaji, New Delhi, 110019, India.
- Institute of Organic Chemistry, Stereochemistry Research Group, HUN-REN Research Centre for Natural Sciences, Magyar tudósok krt. 2, Budapest, H-1117, Hungary.
ORCID-Profile: Jianlin Han
Förderung
- National Natural Science Foundation of China
- National Research, Development and Innovation Office of Hungary
Zitieren
APA
Du, Y., Bian, Y., Baecker, D., Dhawan, G., Semghouli, A., Kiss, L., Zhang, W., Sorochinsky, A. E., Soloshonok, V. A., & Han, J. (2025). Fluorine in the Pharmaceutical Industry: FDA‐Approved Fluorine‐Containing Drugs in 2024. Chemistry – A European Journal, 31(25). https://doi.org/10.1002/chem.202500662
Vancouver
Du Y, Bian Y, Baecker D, Dhawan G, Semghouli A, Kiss L, et al. Fluorine in the Pharmaceutical Industry: FDA‐Approved Fluorine‐Containing Drugs in 2024. Chemistry – A European Journal. 2025;31(25). doi:10.1002/chem.202500662
BibTeX
@article{Du2025,
author = {Du, Youlong and Bian, Yeping and Baecker, Daniel and Dhawan, Gagan and Semghouli, Anas and Kiss, Loránd and Zhang, Wei and Sorochinsky, Alexander E and Soloshonok, Vadim A and Han, Jianlin},
title = {Fluorine in the Pharmaceutical Industry: FDA‐Approved Fluorine‐Containing Drugs in 2024},
journal = {Chemistry – A European Journal},
year = {2025},
volume = {31},
number = {25},
doi = {10.1002/chem.202500662}
}
EUVIMED